Literature DB >> 9008149

Anabolic steroids induce injury and apoptosis of differentiated skeletal muscle.

S Abu-Shakra1, M S Alhalabi, F C Nachtman, R A Schemidt, W S Brusilow.   

Abstract

Apoptosis is an active form of cellular death, or suicide, which plays an important physiologic role during organ development and in cellular turnover in differentiated tissues. Apoptosis has also been demonstrated to occur in several organs in response to hypoxic/ischemic, oxidative, or drug-induced injury and is thus involved in disease pathogenesis. However, it is generally assumed that apoptosis does not occur in differentiated skeletal muscle. Apoptosis has been demonstrated in differentiated myocardial muscle, neonatal skeletal muscle, and skeletal myoblasts in response to injury. We therefore studied differentiated murine C2 skeletal muscle cells that have been injured by supraphysiologic doses (>10 microM) of an anabolic steroid, stanozolol. Stanozolol-injured muscle cells exhibited pathologic features suggestive of apoptosis: cytoplasmic shrinkage and chromatin condensation. Muscle cells also showed positive in situ nick-end labeling of nuclear chromatin, indicating DNA strand breakage. Staining with the DNA-binding dye 33342 (bisbenzimide) also showed chromatin changes characteristic of apoptotic nuclei. Total protein levels measured at 4 and 24 hr post-stanozolol injury was not significantly decreased, indicating absence of cell lysis. Cellular ATP levels (nmol ATP/mg protein) of stanozolol-injured muscle cells, measured 4 and 24 hr postinjury, also did not change significantly. In contrast, necrotic muscle cells, injured by the calcium ionophore A23187 (2 microM), showed a progressive decline in total protein and ATP levels. This study supports two other histologic studies that showed evidence of apoptosis in differentiated skeletal muscle fibers. Our data further suggest that during the early stages of apoptosis, but not necrosis, cellular energy metabolism is preserved.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9008149

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  8 in total

Review 1.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

Review 2.  Apoptosis of skeletal muscle cells and the pathogenesis of myositis: a perspective.

Authors:  C C Liu; J M Ahearn
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

3.  Delayed rhabdomyolysis secondary to anabolic-androgenic steroid use.

Authors:  Amelia Benjamin; Alex Anderson; Sanja Zrelec
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

4.  Cognitive deficits in long-term anabolic-androgenic steroid users.

Authors:  Gen Kanayama; Joseph Kean; James I Hudson; Harrison G Pope
Journal:  Drug Alcohol Depend       Date:  2012-12-14       Impact factor: 4.492

5.  Trauma, systemic inflammatory response syndrome, dietary supplements, illicit steroid use and a questionable malignant hyperthermia reaction.

Authors:  John F Capacchione; Matthew C Radimer; Jeffrey S Sagel; Gregory P Kraus; Nyamkhishig Sambuughin; Sheila M Muldoon
Journal:  Anesth Analg       Date:  2009-03       Impact factor: 5.108

6.  Apoptotic signaling induced by H2O2-mediated oxidative stress in differentiated C2C12 myotubes.

Authors:  Parco M Siu; Yan Wang; Stephen E Alway
Journal:  Life Sci       Date:  2009-02-03       Impact factor: 5.037

Review 7.  Neurotoxicity by synthetic androgen steroids: oxidative stress, apoptosis, and neuropathology: A review.

Authors:  Cristoforo Pomara; Margherita Neri; Stefania Bello; Carmela Fiore; Irene Riezzo; Emanuela Turillazzi
Journal:  Curr Neuropharmacol       Date:  2015-01       Impact factor: 7.363

8.  Anabolic androgenic steroid induced necrotising myopathy.

Authors:  Michael Hughes; Saleh Ahmed
Journal:  Rheumatol Int       Date:  2009-10-27       Impact factor: 2.631

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.